211At-NTR1 compound

211At-NTR1 compound is a preclinical radiopharmaceutical being developed by the ACCELERATE.EU consortium for the treatment of pancreatic ductal adenocarcinoma (PDAC). The compound consists of a ligand targeting the neurotensin receptor 1 (NTR1), which is frequently overexpressed in PDAC and other solid tumors, labeled with the alpha-emitting radioisotope astatine-211 (211At). This targeted alpha therapy (TAT) is designed to deliver high-energy radiation directly to tumor cells, inducing lethal DNA double-strand breaks while minimizing damage to adjacent healthy tissue due to the short range of alpha particles. As a radiotheranostic, it is intended to facilitate both the selection of patients through imaging and the delivery of targeted therapeutic radiation.

Other names

astatine-211-labeled NTR1 compoundastatine211-labeled NTR1 compoundastatine 211-labeled NTR1 compound211At-NTR1 radiotheranostic211At-labeled neurotensin receptor 1 ligand